On Thursday, Avidity Biosciences Inc (NASDAQ: RNA) was 3.49% up from the session before settling in for the closing price of $25.76. A 52-week range for RNA has been $21.51 – $56.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 49.32% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -32.24%. With a float of $111.14 million, this company’s outstanding shares have now reached $119.89 million.
In an organization with 391 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 87.81%, operating margin of -3477.44%, and the pretax margin is -2957.72%.
Avidity Biosciences Inc (RNA) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Avidity Biosciences Inc stocks. The insider ownership of Avidity Biosciences Inc is 7.55%, while institutional ownership is 104.09%. The most recent insider transaction that took place on Apr 01 ’25, was worth 163,486. In this transaction Chief Program Officer of this company sold 5,875 shares at a rate of $27.83, taking the stock ownership to the 50,554 shares. Before that another transaction happened on Mar 20 ’25, when Company’s Chief Medical Officer sold 9,578 for $31.06, making the entire transaction worth $297,491. This insider now owns 72,850 shares in total.
Avidity Biosciences Inc (RNA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.92 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -32.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.06% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
You can see what Avidity Biosciences Inc (RNA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 15.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 294.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.90, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -4.30 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.53 million. That was better than the volume of 1.5 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 73.52%. Additionally, its Average True Range was 2.24.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 21.05%, which indicates a significant decrease from 56.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.18% in the past 14 days, which was higher than the 63.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.11, while its 200-day Moving Average is $38.10. However, in the short run, Avidity Biosciences Inc’s stock first resistance to watch stands at $27.23. Second resistance stands at $27.81. The third major resistance level sits at $28.59. If the price goes on to break the first support level at $25.87, it is likely to go to the next support level at $25.09. Assuming the price breaks the second support level, the third support level stands at $24.51.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
There are 120,212K outstanding shares of the company, which has a market capitalization of 3.20 billion. As of now, sales total 10,900 K while income totals -322,300 K. Its latest quarter income was 2,970 K while its last quarter net income were -102,260 K.
